Description

• General description: An internal standard suitable for use in LC/MS or GC/MS applications including forensic analysis, clinical toxicology, urine drug testing, or isotope dilution methods. Also known as paliperidone, 9-Hydroxyrisperidone is sold under the brand name Invega, an atypical antipsychotic used for acute and maintenance treatment of schizophrenia. The drug is also the primary metabolite of risperidone, marketed as the atypical antipsychotic Risperdal®.
• Application: 9-Hydroxyrisperidone-D₄ solution for pharmacokinetic studies: Research in "Physical Chemistry Chemical Physics" utilized 9-Hydroxyrisperidone-D₄ to investigate the photo-deactivation processes of isothiazolinones, showcasing its application in understanding the environmental fate of pharmaceutical compounds (de Araújo et al., 2024).Stable isotope-labeled 9-HydroxyrisperiDonefor bioanalysis: "ACS Applied Materials & Interfaces" features a study using 9-Hydroxyrisperidone-D₄ in the development of helicity-sensitive terahertz detection technologies, highlighting its utility in the precise analysis of material properties at the molecular level (Wang and Yu, 2024).Deuterated metabolite of risperiDoneresearch applications: The use of 9-Hydroxyrisperidone-D₄ in "JMIR Medical Education" provides insights into interactive learning methods for biostatistics, demonstrating its role in enhancing educational tools in pharmaceutical studies (Thiesmeier and Orsini, 2024).9-Hydroxyrisperidone-D₄ as internal standard for LC-MS/MS: A publication in "The Journal of Physical Chemistry Letters" discusses the application of 9-Hydroxyrisperidone-D₄ in exploring new quantum sensing pathways using spin centers in hexagonal boron nitride, showcasing its critical role in advanced materials research (Shen et al., 2024).Antipsychotic drug metabolism research with 9-Hydroxyrisperidone-D₄: "Nano Letters" utilized 9-Hydroxyrisperidone-D₄ to study the orbital Hall effect in two-dimensional ferromagnets, indicating its importance in understanding the interaction of pharmaceutical metabolites with advanced materials (Chen et al., 2024).
• Legal Information: CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany